Shares of XtalPi Holdings Ltd (02228), a provider of drug discovery and intelligent automation solutions, surged 18.21% on Wednesday as investors reacted positively to the company's plans for a share placement and its involvement in an AI integration project.
XtalPi announced a private placement of 342.3 million shares at HK$6.10 per share, aiming to raise around HK$2.09 billion (US$268.8 million). The proceeds will be used for research and development, product commercialization, and working capital purposes. The new shares represent 8.52% of the company's enlarged issued share capital.
Additionally, XtalPi's subsidiary Shenzhen Jingtai is partnering with state-owned Guangdong Hengjian Investment to advance the implementation of an "AI+" technology and industry integration innovation consortium project. The project focuses on "AI+ Robotic Automation" and aims to build AI research infrastructure for the future development of AI-based industries such as pharmaceuticals, new materials, new energy, and robotics in China's Greater Bay Area and globally.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。